A Phase 1b/2a Two-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination With Gemcitabine in Patients With Advanced or Metastatic Cancer

Trial Profile

A Phase 1b/2a Two-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination With Gemcitabine in Patients With Advanced or Metastatic Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 May 2018

At a glance

  • Drugs LY 2880070 (Primary) ; Gemcitabine
  • Indications Breast cancer; Colon cancer; Colorectal cancer; Ovarian cancer; Rectal cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Esperas Pharma
  • Most Recent Events

    • 24 Apr 2018 Planned number of patients changed from 93 to 133.
    • 22 Feb 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Dec 2018.
    • 06 Nov 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top